Mission awarded $5.2m to advance potential Parkinson’s treatment
The progressive neurodegenerative condition affects around 153,000 people in the UK
Read More
Tag: MTX325
- Pluripotent stem cell trial for Huntington’s disease
- Jascayd gains UK licence for treatment of pulmonary fibrosis
- Grünenthal receives FDA designations for tegacorat in Duchenne muscular dystrophy
- Compass Pathways reports six‑month data confirming durable profile of COMP360
- Ferrer and Prilenia begin confirmatory study of pridopidine in Huntington’s disease
